Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Current Leases (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Current Leases data on record, last reported at $4.1 million in Q4 2025.

  • For Q4 2025, Current Leases fell 45.26% year-over-year to $4.1 million; the TTM value through Dec 2025 reached $4.1 million, down 45.26%, while the annual FY2025 figure was $4.1 million, 45.26% down from the prior year.
  • Current Leases reached $4.1 million in Q4 2025 per TRDA's latest filing, down from $4.4 million in the prior quarter.
  • Across five years, Current Leases topped out at $8.6 million in Q2 2024 and bottomed at $4.1 million in Q4 2025.
  • Average Current Leases over 4 years is $7.2 million, with a median of $7.6 million recorded in 2024.
  • Peak YoY movement for Current Leases: grew 16.87% in 2024, then plummeted 45.26% in 2025.
  • A 4-year view of Current Leases shows it stood at $8.4 million in 2022, then decreased by 5.91% to $7.9 million in 2023, then decreased by 4.43% to $7.6 million in 2024, then plummeted by 45.26% to $4.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $4.1 million in Q4 2025, $4.4 million in Q3 2025, and $5.5 million in Q2 2025.